Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B3bb599180a92b91be23a44f1fe1e1b72> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B3bb599180a92b91be23a44f1fe1e1b72 NCIT_P378 "NCI" @default.
- B3bb599180a92b91be23a44f1fe1e1b72 type Axiom @default.
- B3bb599180a92b91be23a44f1fe1e1b72 annotatedProperty IAO_0000115 @default.
- B3bb599180a92b91be23a44f1fe1e1b72 annotatedSource NCIT_C201084 @default.
- B3bb599180a92b91be23a44f1fe1e1b72 annotatedTarget "An inhalation powder formulation composed of a fixed combination of the furoate salt form of the glucocorticoid fluticasone, the bromide salt form of the muscarinic receptor antagonist umeclidinium, and the triphenylacetate salt form of the long-acting beta-2 adrenergic agonist vilanterol, with anti-inflammatory and bronchodilator activities. Upon oral inhalation of the fluticasone furoate/umeclidinium bromide/vilanterol trifenatate inhalation powder via an inhaler, fluticasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with inflammation. Umeclidinium antagonizes M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilation. Vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells." @default.